Search Bar & Filters
Found 93 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are studying an experimental combination of two drugs, pozelimab and cemdisiran, for adults with paroxysmal nocturnal hemoglobinuria PNH. This study aims to evaluate the long-term safety and effectiveness of this drug combination. It also investigates how the drugs affect the body over time, including possible side effects, drug levels in the blood, and whether the body develops antibodies against the drugs. The study includes two groups patients who completed treatment in a previous related study and patients with a specific genetic variation C5 polymorphism that makes them resistant to other treatments. Participants receive pozelimab with an initial intravenous loading dose on Day 1, followed by ongoing treatment with both study drugs as per the study protocol. The study is open-label and non-randomized. Participants will attend clinic visits and undergo various assessments throughout the study, including blood tests to measure lactate dehydrogenase LDH levels and monitor hemolysis, transfusion needs, hemoglobin levels, fatigue, physical function, and quality of life. Safety is closely monitored by tracking adverse events. The study lasts up to 108 weeks, allowing researchers to observe long-term treatment effects and safety.
Actively Recruiting
Researchers are evaluating alisertib combined with endocrine therapy in adults with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed after at least two prior endocrine treatments. This phase 2 study aims to find the best alisertib dose when used with endocrine therapy and to assess the treatments effectiveness, safety, and how the body processes the drug. The study also seeks to identify specific biomarker groups that may benefit most from the combination therapy. Participants receive alisertib tablets taken orally twice daily on days 1-3, 8-10, and 15-17 in each 28-day cycle along with a chosen endocrine therapy such as anastrozole, letrozole, exemestane, tamoxifen, or fulvestrant following approved dosing schedules. Participants were randomized to different dose groups of alisertib combined with endocrine therapy, with some groups closed to new enrollment after protocol updates. Treatment continues with regular cycles as per the study design. Throughout the study, participants undergo evaluations including tumor response measurements, duration and control of disease, progression-free and overall survival tracked up to 48 months. Safety is monitored by recording adverse events from the first dose through 28 days after the last dose. Researchers also collect pharmacokinetic data and biomarker information to understand treatment effects. The total participation duration aligns with the treatment cycles and follow-up assessments scheduled over several years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.
Actively Recruiting
Healthy Volunteer
Researchers are studying GSK4527363 in a phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. This study includes healthy participants, people with systemic lupus erythematosus SLE, healthy individuals of Chinese and Japanese ancestry, and participants with interstitial lung disease linked to connective tissue disease CTD-ILD. The trial includes multiple groups to understand how the drug behaves across these populations. Participants receive GSK4527363, placebo matching GSK4527363, or belimumab, depending on their group. The study is divided into four parts Part A involves healthy volunteers, Part B includes participants with active SLE, Part C enrolls healthy Chinese and Japanese participants, and Part D involves those with CTD-ILD. Treatments and assessments occur over different durations, up to 52 weeks for healthy participants and up to 68 weeks for those with SLE or CTD-ILD. During the study, participants undergo medical evaluations including physical exams, lab tests, vital signs monitoring, and 12-lead ECGs. Researchers track adverse events, immune responses, drug levels in the blood, and changes in cytokine levels. Safety and tolerability are monitored closely through these measures. The total participation time varies by group, extending up to 68 weeks for some. This comprehensive monitoring helps assess the drugs effects and safety in diverse participants.
1-10 of 93
1